Bortezomib, a proteasome inhibitor that was approved by the FDA for multiple myeloma treatment in 2008, indirectly inhibits the transcriptional activity of HIF1 and even causes radiosensitivity in tumor cells [82]. This evidence concerns the gene HIF1A and plasma cell myeloma.